Form 4: Zentalis CMO Sells Shares for Tax Obligations

Zentalis Pharmaceuticals' Chief Medical Officer, Ingmar Bruns, sold common stock to cover tax withholding obligations from RSU vesting.

Summary

• Ingmar Bruns, Chief Medical Officer of Zentalis Pharmaceuticals, Inc. (ZNTL), reported sales of common stock.
• On February 6, 2026, 2,962 shares were sold at a price of $2.4297 per share.
• On February 9, 2026, an additional 335 shares were sold at a price of $2.3929 per share.
• These sales were automatic and executed by the Issuer to cover tax withholding obligations associated with the vesting and settlement of previously granted restricted stock units (RSUs).
• Following these transactions, Ingmar Bruns beneficially owns 33,332 shares of Zentalis Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is administrative, covering tax obligations from RSU vesting, and does not indicate a change in management's confidence or the company's operational performance.

Positives

• The underlying event, the vesting of restricted stock units, represents a form of compensation for the Chief Medical Officer, indicating continued alignment of executive incentives with company performance.

Negatives

• No direct negatives from the reported transactions, as the sales were non-discretionary and for tax purposes.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.

Industry Context

StockSavvy.ai notes that sales of common stock by executives to cover tax withholding obligations upon the vesting of restricted stock units are a standard and routine practice across industries. This type of transaction is typically non-discretionary and does not reflect a change in the executive's investment sentiment towards the company.

Related Party Transactions

• This filing details an insider transaction (sale of shares by an officer), which is a type of related party dealing. The specific context is a non-discretionary sale for tax purposes, which is a common and expected event rather than a unique related party transaction requiring special scrutiny beyond the standard insider trading rules.

Stakeholder Impact

• Minimal impact on shareholders, employees, customers, suppliers, or creditors, as this is a routine, non-discretionary transaction for tax purposes related to executive compensation.

Key Dates

Keywords

Zentalis Pharmaceuticals, ZNTL, Form 4, insider trading, stock sale, Chief Medical Officer, Ingmar Bruns, restricted stock units, RSU, equity compensation, tax withholding